Translating science
into innovative
diagnostic solutions
Latest news
Upstate Medical gets FDA approval for Wider Use of its Saliva Swab COVID-19 Test
CNY BUSINESS JOURNAL
Quadrant Biosciences Receives FDA Emergency Authorization for New COVID-19 Saliva Test
CISION PR NEWSWIRE
NYS GOVERNOR'S OFFICE
Cape Vincent native heads Quadrant Biosciences, lab company on cutting edge of COVID research
NNY 360
EIN PRESSWIRE
Renowned autism researcher Dr. Thomas Frazier joins Quadrant Biosciences Clinical Advisory Board
EIN PRESSWIRE
NY Governor's Office
Our aim is to develop solutions for important global health issues
Quadrant Biosciences is a molecular diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform.
Finally, we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.






Be part of a study
Be part of a study
Autism research study
Children ages 18 months to 48 months with an autism diagnosis, developmental delays, or a suspicion of autism are eligible.
Parkinson’s Study
Help us learn how to better diagnose Parkinson’s Disease at an earlier stage.